NVCT – nuvectis pharma, inc. (US:NASDAQ)
Stock Stats
News
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: BENTSUR RON
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Kaplan Matthew L.
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Sanchez Juan
Form 8-K Nuvectis Pharma, Inc. For: Nov 04
Form 10-Q Nuvectis Pharma, Inc. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.